Jakafi 10 MG tablet 60S
Ended Awarded Last action
- Contract number
- SPE2DR26FCRL9
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $24,730
Award facts
- Contract value 100% obligated
- $24,729.64 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order valued at $24,729.64 to DMS Pharmaceutical Group Inc. for JAKAFI 10 MG tablets (60-count packages) on December 3, 2025, with an ultimate completion date of December 4, 2025. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, was selected without a set-aside designation, demonstrating the company's competitive capability in unrestricted federal procurement. This delivery order was issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (IDC) with the DLA, designated SPE2DR under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, which was awarded on November 13, 2025, with a $499,999,999 ceiling value and completion date of December 31, 2036.
The PPV-G GEN V represents a $30.3 billion federal acquisition strategy managed by the DLA to establish regional prime vendor contractors supplying pharmaceutical products to Department of Defense healthcare facilities worldwide. As a critical pharmaceutical supplier within the federal military medical system, DMS Pharmaceutical Group maintains a comprehensive product portfolio encompassing branded and generic prescription medications, biologics, vaccines, specialty pharmaceuticals, and medical consumables to support recurring medical supply needs across DoD installations globally. The company's established performance on numerous delivery orders since October 2025 demonstrates its operational capability to fulfill the diverse and specialized pharmaceutical requirements of military healthcare operations with no identified subcontractor relationships.
Quick answers
Who was awarded contract SPE2DR26FCRL9?
SPE2DR26FCRL9 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 3, 2025.
How much is contract SPE2DR26FCRL9 worth?
The government has obligated $24,730 on SPE2DR26FCRL9.
Is contract SPE2DR26FCRL9 an order under another contract?
Yes. SPE2DR26FCRL9 is a delivery order under SPE2DR25D9168, an indefinite delivery contract.
Was contract SPE2DR26FCRL9 competed?
The extent of competition for SPE2DR26FCRL9 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award